Scarica l'app Stockscreener
79.74
3.31%
-2.73
Precedente Chiudi:
$82.47
Aprire:
$83.77
Volume 24 ore:
1.22M
Relative Volume:
1.06
Capitalizzazione di mercato:
$9.94B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-17.33
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
-5.07%
1M Prestazione:
-9.56%
6M Prestazione:
-0.10%
1 anno Prestazione:
+10.35%
Intervallo 1D:
$79.51
$84.01
Intervallo di 1 settimana:
$79.51
$85.22
Portata 52W:
$58.10
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Confronta PCVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
79.74 | 9.94B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $670,800.00 in Stock - MarketBeat
Vaxcyte president and CFO sells $670,822 in stock By Investing.com - Investing.com South Africa
State of New Jersey Common Pension Fund D Purchases 5,427 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte president and CFO sells $670,822 in stock - Investing.com India
Vaxcyte Executive Sells Shares Under Trading Plan - TradingView
Vaxcyte (PCVX) to Release Quarterly Earnings on Tuesday - MarketBeat
TimesSquare Capital Management LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Lowered by Banque Pictet & Cie SA - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Allspring Global Investments Holdings LLC - MarketBeat
Vaxcyte SVP Mikhail Eydelman sells $450k in stock - MSN
Vaxcyte's (PCVX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
WCM Investment Management LLC Sells 68,753 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
Vaxcyte, Inc. to Announce Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Vaxcyte Sets Stage for Major Q4 Revelations: Vaccine Innovation Updates & Financial Deep-Dive Coming - StockTitan
abrdn plc Buys 141,994 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte COO Jim Wassil sells $689,790 in stock - MSN
Calamos Advisors LLC Lowers Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $689,760.00 in Stock - MarketBeat
Vaxcyte advances to final stage in infant vaccine study - MSN
Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance
Jennison Associates LLC Buys 9,121 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
12 Best Healthcare Stocks to Buy According to Analysts - Insider Monkey
Vaxcyte SVP Mikhail Eydelman sells $450k in stock By Investing.com - Investing.com Nigeria
Vaxcyte’s Promising Pipeline and Growth Potential Justifies Buy Rating - TipRanks
Vaxcyte advances to final stage in infant vaccine study By Investing.com - Investing.com Australia
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 - Yahoo Finance
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants - Clinical Trials Arena
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study - GlobeNewswire
Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage - Marketscreener.com
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - The Manila Times
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vaxcyte Inc Azioni (PCVX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Feb 18 '25 |
Sale |
83.85 |
8,000 |
670,823 |
109,491 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):